Anna B.
Halpern
M.D.
Fred Hutch
825 Eastlake Ave E
Box LG-700
Seattle, WA 98109
Education, training, board certifications
- M.D., Brown University
- Residency, University of Chicago
- Fellowship, UW/Fred Hutch
- Internal Medicine, American Board of Internal Medicine
- Oncology, American Board of Internal Medicine
- Hematology, American Board of Internal Medicine
Clinical expertise
- Hematologic malignancies
- Acute myeloid leukemia
- Blood disorders
- Polycythemia vera
- Myelofibrosis
- Essential thrombocytosis
- Myelodysplastic syndrome
- Myeloproliferative disorder
Affiliations
- University of Washington
- Fred Hutchinson Cancer Center - Faculty & Labs
- Fred Hutchinson Cancer Center - Provider
publications
Clinical and/or research interests
Dr. Anna Halpern's clinical interests include myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis), myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Dr. Halpern conducts clinical and outcomes research in myieloproliferatiave neoplasms, MDS and AML. Her overarching research aim is to improve the outcomes of adults with hematologic malignancies via the development and testing of evidence-based, rational therapies that are tailored to individual patients. To this end, she designs and conducts clinical trials testing novel care concepts for patients with myeloid neoplasms and uses large databases to study systems-issues on a broader scale, such as risk factors for toxicities from treatment. She is currently the Principal Investigator for multiple clinical trials for advanced myeloid neoplasms.